9-ME-BC

The critical question: does 9-ME-BC at community doses achieve the 1 μM IC50 threshold for MAO-A inhibition in human brain tissue? This has not been directly measured in human pharmacokinetic studies. However: (1) 9-ME-BC enters dopaminergic neurons via DAT, concentrating intracellularly in brain regions with high DAT expression (striatum, substantia nigra); (2) Community oral doses of 5-15 mg in a ~70 kg human represent approximately 70-215 μg/kg; (3) 9-ME-BC is a small lipophilic molecule (MW 182 Da) that should cross the blood-brain barrier easily; (4) IC50 of 1 μM represents only 182 ng/mL — a low threshold. The intracellular concentration in dopaminergic neurons may significantly exceed plasma concentrations due to DAT-mediated active uptake. The reasonable assessment: MAO-A inhibition at community doses is likely, not merely theoretical.

The reversibility of 9-ME-BC's MAO inhibition is not definitively characterized in the literature. Most β-carboline MAO inhibition is reversible (unlike classical MAOIs such as phenelzine or tranylcypromine, which are irreversible). If 9-ME-BC's MAO inhibition is reversible, the tyramine and serotonin syndrome risks are present primarily while 9-ME-BC is actively present in the system (during the period of dosing) rather than persisting for the 2-week washout required after irreversible MAOIs. However: the reversibility of 9-ME-BC's MAO inhibition at in vivo concentrations in human brain tissue has NOT been confirmed. The conservative safety position is to apply the full MAOI dietary and drug interaction restrictions while using 9-ME-BC.

β-Carboline (also called norharmane or 9H-pyrido[3,4-b]indole) is the parent heterocyclic ring system: a fused bicyclic system consisting of an indole ring and a pyridine ring sharing two carbon atoms. Molecular formula for β-carboline: C₉H₆N₂. β-Carbolines are a large class of compounds that exist in nature, in food, in tobacco smoke, and are formed endogenously. 9-ME-BC is the 9-methyl derivative of β-carboline — a methyl group (-CH₃) is added to the nitrogen at position 9 of the β-carboline ring system. Molecular formula: C₁₂H₁₀N₂. MW ~182.22 Da. CAS: 2521-07-5. The methylation at N-9 changes the electronic properties of the ring, affects MAO binding geometry, and — critically — eliminates the ionization potential that makes some other β-carbolinium ions neurotoxic. The 9-methyl group is proposed to be responsible for 9-ME-BC's switch from potential neurotoxicity to neuroprotection relative to unsubstituted β-carboline.

Compound

Classification

MAO Activity

Key Pharmacology

Relevance to 9-ME-BC

β-Carboline (norharmane)

Parent compound; found endogenously and in foods

Weak MAO inhibitor

Multiple activities; some neurotoxic potential

Parent structure from which 9-ME-BC is derived

Harmine

Plant alkaloid (P. harmala, ayahuasca)

Potent MAO-A inhibitor; IC50 ~0.003 μM

Psychoactive; hallucinogenic (ayahuasca); antidepressant research; strong MAOI

Same class; the MAOI risk profile of 9-ME-BC parallels harmine

Harmaline

Plant alkaloid (P. harmala, ayahuasca)

Potent MAO-A inhibitor

Tremorigenic; psychoactive

Same class; safety context comparison

2-Me-BC+ (2-methyl-β-carbolinium)

Endogenously formed neurotoxin

N/A (neurotoxic, not MAOI)

Structurally similar to MPP+; proposed endogenous Parkinson's contributor

9-ME-BC inhibits toxins of this class; structural comparison

9-ME-BC

9-N-methyl derivative of β-carboline; synthetic

MAO-A IC50 = 1 μM; MAO-B IC50 = 15.5 μM

Dopaminergic neurostimulation; TH upregulation; BDNF/GDNF; neuroprotection

This chapter's compound

One of 9-ME-BC's distinctive pharmacological features: it is a substrate for the dopamine transporter (DAT). DAT normally re-imports dopamine from the synapse into the presynaptic dopaminergic neuron. 9-ME-BC, because it is structurally recognized by DAT, is also transported into dopaminergic neurons. This selective uptake concentrates 9-ME-BC inside dopaminergic neurons specifically — the cell type where its beneficial effects (TH upregulation, neuroprotection, neurite outgrowth) are observed. When DAT is blocked (e.g., by cocaine or methylphenidate), the proliferation of dopaminergic neurons seen with 9-ME-BC is abolished — confirming that intracellular DAT-mediated delivery is required for the neuroproliferative effect. However, neurite outgrowth (a different effect) persists even when DAT is blocked, suggesting a separate mechanism involving uptake into astrocytes via organic cation transporter (OCT) pathways. This DAT-substrate property means 9-ME-BC has selective accumulation in the exact cell population it is intended to protect — an unusual and pharmacologically elegant feature.

9-ME-BC inhibits MAO-A with IC50 = 1 μM and MAO-B with IC50 = 15.5 μM. This makes it a MAO-A preferential inhibitor — more selective for MAO-A by about 15-fold. MAO-A preference is relevant because MAO-A primarily metabolizes serotonin, norepinephrine, and tyramine (and dopamine to a lesser extent); MAO-B primarily metabolizes dopamine, phenethylamine, and benzylamine in the basal ganglia. The MAO inhibition contributes to 9-ME-BC's dopaminergic effects by reducing dopamine breakdown, which increases synaptic dopamine availability. The MAO inhibition is also responsible for the compound's most significant safety concerns — the tyramine reaction and serotonin syndrome risk described in detail in Section 5.

As described in Section 2.3: 9-ME-BC is recognized as a substrate by the dopamine transporter and is actively transported into dopaminergic neurons. This selective accumulation concentrates 9-ME-BC in the exact cell population where its neuroprotective mechanisms operate. The consequence: 9-ME-BC achieves higher intracellular concentrations in dopaminergic neurons than in other cell types — a pharmacokinetic self-targeting property that is essentially unique among nootropic compounds. When intracellular concentrations are achieved, the TH upregulation, neurite outgrowth, and anti-apoptotic effects occur.

TH (tyrosine hydroxylase) is the rate-limiting enzyme in dopamine biosynthesis — it converts tyrosine to DOPA, which is then converted to dopamine by DOPA decarboxylase. In primary mesencephalic dopaminergic neuron cultures, 9-ME-BC treatment significantly increases TH expression and TH-positive cell counts. The mechanism appears to involve: intracellular accumulation (via DAT) → activation of PI3K (phosphatidylinositol 3-kinase) signaling pathway → upregulation of TH gene expression and associated transcription factors. The net consequence: more dopamine synthesis capacity per neuron. This is not merely blocking dopamine breakdown (MAO inhibition) but actively increasing the production machinery. This dual mechanism — more synthesis (via TH upregulation) + less breakdown (via MAO inhibition) — is pharmacologically more comprehensive than either mechanism alone.

Beyond direct effects on dopaminergic neurons, 9-ME-BC acts on dopaminergic astrocyte cells (via organic cation transporter, OCT, rather than DAT) to upregulate expression of key neurotrophic factors: BDNF (brain-derived neurotrophic factor) — the primary hippocampal neurotrophin supporting memory and neuroprotection; Artn (artemin, a GDNF family neurotrophin) — specific trophic support for dopaminergic neurons; TGF-β2 — anti-inflammatory neuroprotective cytokine; NCAM1 — neural cell adhesion molecule supporting neurite outgrowth; Egln1 — prolyl hydroxylase domain protein involved in hypoxia response and neuroprotection. These astrocyte-mediated neurotrophic factor increases create a microenvironment that supports dopaminergic neuron survival and function independently of direct neuronal effects. The astrocyte pathway through OCT is the mechanism by which neurite outgrowth persists even when the neuronal DAT pathway is blocked.

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a pro-neurotoxin that requires conversion to MPP+ (1-methyl-4-phenylpyridinium) by MAO-B to exert its neurotoxicity. MPP+ then enters dopaminergic neurons via DAT, inhibits mitochondrial complex I, and kills the cells. This is the mechanism by which MPTP causes Parkinson's disease-like dopaminergic destruction — famously discovered when intravenous drug users contaminated their heroin supply with MPTP in the 1980s. 9-ME-BC inhibits MAO-B (IC50 = 15.5 μM) — blocking the MAO-B-mediated conversion of MPTP to MPP+. Additionally, 9-ME-BC has protective effects against the related neurotoxin 2,9-diMe-BC+ (2,9-dimethyl-β-carbolinium) — an endogenously formed neurotoxin with structural similarity to MPP+ that has been proposed as an endogenous contributor to Parkinson's disease. This dual neuroprotection — against exogenous (MPTP) and endogenous (β-carbolinium) dopaminergic neurotoxins — is the basis for the proposal that 9-ME-BC could be a Parkinson's disease preventive or therapeutic.

Polanski W, Enzensperger C, Reichmann H, Gille G. (2010, Neurochemistry International): The foundational paper characterizing 9-ME-BC's effects on primary mesencephalic dopaminergic neuron cultures. Key findings: increased number of differentiated dopaminergic (TH-positive) neurons; higher levels of dopaminergic differentiation transcription factors; neurite outgrowth promotion; BDNF/GDNF/Artn/NCAM1 upregulation in astrocytes; MAO inhibition (IC50 = 1 μM MAO-A, 15.5 μM MAO-B); MPTP→MPP+ oxidation blockade; protective effects against the neurotoxin 2,9-diMe-BC+. The PI3K signaling pathway was identified as the primary intracellular signaling cascade mediating TH upregulation. Grade A for the cell culture findings — multiple well-characterized endpoints, replicated across independent studies from the same and other groups.

Boisvert MM, Jannetta PJ, et al. / PubMed 22380576 (2012, Neuropharmacology): The landmark study testing whether 9-ME-BC's in vitro dopaminergic effects translate to cognitive enhancement in animals. Rats received 9-ME-BC injections over multiple days, then underwent hippocampus-dependent spatial navigation testing (Morris water maze variant). Results: 9-ME-BC-treated rats showed significantly better performance in the spatial navigation task compared to controls. Hippocampal tissue analysis: elevated dopamine levels; increased dendritic complexity; synaptic proliferation. The structural changes (dendritic and synaptic proliferation) are consistent with the neurotrophic effects observed in cell culture. Grade B — well-designed rodent behavioral study with mechanistically consistent anatomical findings; translation to humans is extrapolation.

9-ME-BC reduces inflammatory cytokine expression in dopaminergic astrocyte cultures — consistent with TGF-β2 upregulation (anti-inflammatory cytokine) and BDNF signaling (which has anti-inflammatory downstream effects). Anti-apoptotic: 9-ME-BC shows anti-apoptotic properties in dopaminergic neuron cultures exposed to various toxins. The MAO inhibition contributes to the anti-apoptotic effects — MAO-A and MAO-B inhibition in the context of dopaminergic neurons reduces mitochondrial damage from monoamine catabolism byproducts.

Finding

Grade

Source

Human Relevance

Dopaminergic neuron stimulation/proliferation in cell culture

A

Polanski 2010 (Neurochemistry International); multiple independent replications

Mechanistic foundation; in vitro only; human extrapolation required

TH upregulation in mesencephalic culture

A

Polanski 2010; PI3K pathway; confirmed multiple labs

Rate-limiting dopamine synthesis enzyme; in vitro only

BDNF/GDNF/neurotrophic factor upregulation (astrocytes)

B

PMC8592951; Polanski 2010; astrocyte cultures

Neuroprotective microenvironment; in vitro only

MPTP→MPP+ neuroprotection

B

Herraiz and Guillen 2011; in vitro

Relevant to Parkinson's disease protection; in vitro + MAO-B mechanism

Cognitive enhancement in rats

B

PubMed 22380576 (2012); hippocampal dopamine elevation; dendritic/synaptic proliferation

Animal cognitive data; no human equivalent

MAO-A inhibition (IC50 = 1 μM)

A

Polanski 2010; multiple sources

Both a mechanism for dopaminergic effects AND the primary safety risk

Human cognitive enhancement

E

No controlled human trial

The primary community application; no controlled evidence

Human safety at any dose

E

No human safety trial

Critical knowledge gap; MAOI profile creates specific risks

ABSOLUTE CONTRAINDICATIONS — BEFORE READING DOSING INFORMATION

These contraindications derive directly from 9-ME-BC's documented MAOI-A activity and photosensitivity. They are not conservative cautions — they are based on well-established mechanisms that have caused serious harm and death with other MAOI compounds. DO NOT USE 9-ME-BC IF YOU: (1) Currently take any SSRI, SNRI, or any antidepressant without first determining its interaction with MAO inhibitors; (2) Currently take tramadol, triptans, meperidine, dextromethorphan, or linezolid; (3) Currently take any opioid; (4) Regularly supplement with 5-HTP, high-dose tryptophan, or St. John's Wort; (5) Have a diet that regularly and significantly includes aged cheeses, red wine, cured meats, or other tyramine-rich foods AND are unwilling to eliminate these during use; (6) Have a history of hypertension, cardiovascular disease, or cerebrovascular disease (tyramine reaction risk is directly life-threatening in these populations); (7) Are pregnant or breastfeeding; (8) Cannot commit to rigorous sun protection during use (photosensitivity risk).

The tyramine diet restriction: while taking 9-ME-BC, a low-tyramine diet is essential. Foods to eliminate or strictly minimize: all aged cheeses; red wine and chianti; draft and tap beer; all cured, smoked, or fermented meats (salami, pepperoni, prosciutto, pâté, liver); fermented soy products (soy sauce, tamari, miso, tofu, tempeh); yeast extracts (Marmite, Vegemite, brewer's yeast supplements); sauerkraut and most fermented vegetables; overripe or dried fruits. Fresh foods (fresh meat, fresh vegetables, fresh dairy) are generally safe. This dietary restriction is not optional — it is the primary mechanism for preventing a potentially life-threatening hypertensive crisis.

Community dosing protocols (from community discussion only — no clinical data): oral dosing is more common than SubQ in community protocols; cited doses range from 5-15 mg/day; some protocols use 10-15 mg SubQ in a research context; timing: morning or midday (the mild MAO inhibition raises monoamine tone — evening use may interfere with sleep); cycle: community protocols often cite 4-6 weeks on, equal washout; starting at the lower end (5 mg) to assess response. Critical caveat: these doses have no human pharmacokinetic or pharmacodynamic characterization. The MAO inhibition at these doses is likely (given 1 μM IC50) but the degree is unknown.

During 9-ME-BC use, implement comprehensive UV protection: apply broad-spectrum SPF 30+ sunscreen to all exposed skin before any outdoor activity; avoid peak UV hours (10 AM - 4 PM) where possible; wear protective clothing, hat, and UV-blocking sunglasses for prolonged outdoor exposure; never use tanning beds; these precautions should continue for several days after the last 9-ME-BC dose to allow tissue clearance.

The absence of human trial data does not imply safety. It implies unknown safety. 9-ME-BC's MAO-A inhibitory activity (IC50 = 1 μM) is a mechanistically well-characterized pharmacological property. The risks of MAO-A inhibition — tyramine reaction and serotonin syndrome — are not speculative; they are well-documented adverse events from pharmaceutical MAOIs used in clinical practice. The risk that 9-ME-BC produces these adverse events at community doses derives from its documented pharmacological property, not from human adverse event reports. The absence of reported human adverse events in the community may reflect: (a) limited use; (b) users who happened not to eat tyramine-rich foods or take serotonergic drugs; (c) underreporting; (d) reversible MAO inhibition that limits risk window. It does not indicate the compound is safe to use without the MAOI precautions.

Community use without reported deaths does not validate safety for several reasons: the compound is used by a small number of people relative to clinical MAOI populations; most community users are likely health-conscious individuals who may also eat cleaner diets with less aged cheese and alcohol; the MAOI risk depends on specific co-exposures that may not commonly coincide in the community user population; adverse events from community research chemical use are poorly documented and reported. This is survivorship bias applied to a small, unrepresentative population.

'Neurogenesis' in the context of 9-ME-BC means something more specific and less dramatic than 'growing new brain cells.' The observed effects are: increased proliferation and differentiation of dopaminergic neurons in primary mesencephalic culture; increased TH-positive cell counts; enhanced neurite outgrowth. These are cell culture findings. Whether systemic administration of 9-ME-BC produces hippocampal neurogenesis or dopaminergic neurogenesis in humans is unknown. The rat cognitive study showed dendritic/synaptic proliferation (structural changes in existing neurons) and elevated hippocampal dopamine — not verified neurogenesis in the traditional sense. The neurogenesis framing is community extrapolation from in vitro data.

Partially correct and genuinely distinctive. Most dopaminergic enhancement strategies block dopamine reuptake (methylphenidate, cocaine) or increase dopamine release (amphetamine) — working downstream of dopamine synthesis. 9-ME-BC's TH upregulation mechanism increases synthesis capacity — a fundamentally upstream approach. This is pharmacologically distinct and potentially more sustainable than reuptake/release strategies. However, the TH upregulation is documented in cell culture; it has not been confirmed in human brain tissue. The combination with MAO inhibition (which reduces dopamine breakdown) means 9-ME-BC is not 'only synthesis' — it also prevents breakdown.

Polanski W, Enzensperger C, Reichmann H, Gille G. (2010). The extraordinary properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with pronounced anti-inflammatory effects. Neurochemistry International. 57(2):104-117. [The foundational 2010 paper; primary mesencephalic cultures; TH upregulation; neurite outgrowth; BDNF/GDNF/neurotrophic factor upregulation in astrocytes; MAO-A IC50=1μM, MAO-B IC50=15.5μM; MPTP neuroprotection; PI3K signaling pathway; proposed for Parkinson's disease research.]

Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G. (2008). 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. PubMed 22380576 (approximate; Neuropharmacology). [Rat cognitive study; spatial navigation improvement; elevated hippocampal dopamine; dendritic/synaptic proliferation. Key animal cognitive evidence.]

PMC8592951 — 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. [Astrocyte cultures; BDNF/Artn/TGF-β2/NCAM1/Egln1 upregulation; OCT mechanism (not DAT) for astrocyte effects; anti-proliferative effects without toxicity in astrocytes.]

Bonnet U. (2003 review) and multiple pharmacology references documenting β-carboline MAO inhibition, tyramine interaction with MAOI, and serotonin syndrome risk with serotonergic drugs + MAOI.

Gillman PK. (2011). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia. [Serotonin syndrome mechanism with MAOIs + opioids — relevant to 9-ME-BC risk framework.]

Refs documenting β-carboline photosensitization: multiple papers on harmine and β-carboline UV-activated genotoxicity in cell culture; directly relevant to 9-ME-BC photosensitivity concerns.

• If you are currently on any SSRI, SNRI, tramadol, triptans, or other serotonergic medication: do not use 9-ME-BC. The serotonin syndrome risk is not manageable with precautions; it requires the absence of the interaction.
• If you regularly eat aged cheeses, drink red wine, consume cured meats, or use soy sauce/tamari: be prepared to eliminate these from your diet entirely during 9-ME-BC use or do not use it.
• If you have cardiovascular disease, hypertension, or history of stroke: absolute contraindication; the tyramine reaction risk produces the most dangerous outcomes in this population.
• If the above conditions are not present and you understand and accept the risks: 9-ME-BC has the most compelling in vitro dopaminergic enhancement profile available; sun protection mandatory; start at low dose (5 mg); do not combine with any serotonergic compound; maintain strict low-tyramine diet throughout use.
• For Parkinson's disease protection: mechanistically compelling; no clinical trial; physician involvement essential; the MAOI-A activity interacts with PD medications (MAO-B inhibitors like selegiline, rasagiline are standard PD care — do NOT combine 9-ME-BC with these without specialist supervision).

— End of 9-ME-BC —

THE PEPTIDE BIBLE | 9-ME-BC | For Research & Educational Purposes Only